2nd Nov 2009 07:00
|
For immediate release |
2 November 2009 |
ABCAM PLC
("Abcam" or "the Company")
AGM Statement
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is holding its Annual General Meeting at 10.00 am this morning. As previously announced the Company's Chairman, David Cleevely, will be retiring from the Board at the AGM. Dr Cleevely will make the following statement at the meeting:
"I am very proud of Abcam's achievements since we established the Company 11 years ago. We have built a global business characterised by rapidly increasing demand for its products and a strong customer base. In recent times the strength of our business model has come to the fore and the robust and defensive nature of the markets we serve has been demonstrated."
"I am pleased to report that the Company has continued to perform well in the new financial year. Underlying sales growth is in line with our expectations as demand for our products increases and we are benefiting from the weakness of sterling over the comparative period last year. The challenges to the global economy as a result of the recession require a degree of caution, but the Board looks forward to another successful year."
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its four operating companies.
About antibodies
Antibodies are proteins produced by white blood cells in response to the introduction of a foreign body known as an antigen. Antibodies, which have a wide variety of uses in research, diagnostics and therapeutics, are used by bioscientists in research into disease and into the human genome, where they are used to mark and identify specific cells and other living matter. The number of human antibodies of use in research is potentially greater than one million.
Related Shares:
ABC.L